Spatially resolved cell sorting for advanced tumour analysis
by Dr Yoonyoung Lee
Tumour heterogeneity and spatial organization within the tumour micro-environment are important factors influencing cancer progression and therapeutic response. Spatially resolved cell sorting technologies enable selective isolation of spatially defined cellular populations directly from tissue sections while preserving tissue context for downstream molecular analysis, thus supporting advances in tumour characterization and precision oncology.
Spatially resolved cell sorting
Spatially resolved cell sorting refers to a group of emerging technologies designed to selectively isolate cells or tissue regions directly from intact tissue sections while preserving spatial localization and tissue architecture. Unlike conventional dissociation-based workflows, these approaches aim to maintain the relationship between cellular phenotype, morphology and molecular characteristics within the tissue microenvironment.
Figure 1. The challenge of tumour heterogeneity and spatial complexity.
Diverse cell populations and their spatial organization within the tumour microenvironment influence cancer progression and therapeutic response.
Tumour heterogeneity and spatial complexity
Cancer tissues are composed of highly heterogeneous cellular populations, including malignant cells, immune cells, stromal cells and vascular components (Fig. 1). The spatial organization of these cellular populations within the tumour microenvironment plays a critical role in tumour progression, metastasis and therapeutic response. Increasing evidence suggests that not only the presence of specific cell populations, but also their spatial localization and interactions, can influence clinical outcomes.
For example, the distribution of tumour-infiltrating lymphocytes and immune-suppressive cell populations has been associated with responses to immunotherapy in several cancer types [1]. Similarly, tumour margins and localized microenvironments may contain biologically distinct cell populations linked to invasion, recurrence or treatment resistance. As precision oncology continues to evolve, there is growing interest in technologies capable of preserving and interrogating spatial information directly within tissue specimens.
Traditional pathology: visualizing form, missing molecular depth
Histopathology and immunohistochemistry remain foundational tools in clinical pathology laboratories, enabling visualization of tissue architecture and clinically relevant biomarker expression within tumour tissues. These approaches preserve spatial information and are widely used for tumour classification and clinical decision-making. However, they are often limited in the number of biomarkers that can be analysed simultaneously and may provide limited molecular information beyond conventional histopathological assessment.
The blind spot of bulk sequencing
To overcome the limited molecular information provided by conventional histopathological assessment, molecular profiling technologies such as next-generation sequencing have been widely adopted in cancer research and translational oncology. These approaches enable detailed characterization of genomic and transcriptomic alterations and have significantly expanded understanding of tumour heterogeneity, molecular subtypes and disease-associated pathways across various cancer types. However, conventional bulk tissue sequencing workflows often generate averaged molecular signals across heterogeneous tissue populations. As a result, spatially localized tumour subpopulations, stromal compartments and immunecell niches with important biological or clinical significance may become obscured during tissue processing.
Lost in dissociation: limitations of tissue disruption
Flow cytometry-based cell sorting technologies, which played an important role in the transition from bulk tissue analysis to single-cell resolution analysis, are widely used for high-throughput phenotypic analysis and selective isolation of cellular populations for downstream molecular assays. However, these workflows generally require tissue dissociation into single-cell suspensions, resulting in disruption of tissue architecture and loss of spatial context. In addition, fragile or spatially localized cellular populations may be altered or under-represented during sample preparation, which limits comprehensive characterization of spatially organized tumour biology.
The spatial revolution: from tissue mapping to precision sorting
To address these limitations, emerging spatial analysis technologies have become an increasingly important field in cancer research and molecular pathology. Broadly, current spatially resolved molecular analysis approaches can be divided into mapping-based technologies and targeted isolation approaches. Mapping-based technologies include capture-based spatial transcriptomic platforms such as Visium (10x Genomics) [2], as well as imaging-based approaches using multiplex or sequential fluorescence in situ hybridization (FISH). These technologies enable large-scale visualization of gene expression patterns directly within tissue sections, providing valuable information regarding spatial organization and molecular heterogeneity across tumour tissues.
In contrast, targeted isolation approaches aim to selectively recover specific cells or tissue regions of interest for downstream molecular analysis. Technologies such as laser capture microdissection (LCM) have long supported targeted tissue isolation workflows through laser-based tissue dissection methods [3]. More recently, emerging imaging-guided approaches have enabled selective isolation and recovery of morphologically or spatially defined cellular populations directly from tissue sections while preserving tissue-context information for downstream molecular characterization [4].
From vision to isolation: how spatial sorting works
Spatial cell sorting workflows generally integrate two key steps (Fig. 2):
1. Tissue architecture is visualized using histological or molecular staining methods such as haematoxylin and eosin (H&E), immuno-fluorescence and immunohistochemistry. Regions of interest may then be identified based on tissue morphology, biomarker expression or AI-assisted image analysis.
2. Spatially defined cellular populations or tissue regions of interest are selectively isolated for downstream molecular analysis. Various technological approaches, including near-infrared laser-based systems, have been developed for selective recovery of spatially defined cellular populations while supporting downstream sequencing applications.
Spatial profiling of heterogeneous tumour microenvironments
Spatially resolved cell sorting technologies are increasingly being used to connect tissue morphology with downstream molecular profiling approaches such as RNA sequencing and epitranscriptomic analysis. By integrating imaging-based tissue assessment with sequencing-compatible workflows, these approaches may support more detailed characterization of heterogeneous tumour micro-environments in both clinical and translational oncology settings.
Recent studies have highlighted the potential of these approaches across multiple tumour types. In nasopharyngeal carcinoma (NPC), researchers combined LCM with RNA sequencing to selectively profile histologically defined tumour epithelial regions and surrounding stromal compartments. This approach revealed localized activation of fibroblast growth factor (FGF) and noncanonical NF-κB signalling pathways within tumour epithelial populations, thereby illustrating how spatially resolved profiling can uncover molecular programs that may be obscured in bulk analyses [5].
Similar approaches have also been applied in triple-negative breast cancer (TNBC). Using imaging-guided spatial epitranscriptomic analysis, investigators have been able to selectively characterize immuno-fluorescence-defined cancer stem cell-like microniches containing CD44- and ALDH1-positive cellular populations. Integration of spatial staining information with downstream epitranscriptomic analysis identified distinct adenosine-to-inosine (A-to-I) RNA editing signatures within spatially localized tumour microniches, including editing events associated with ferroptosis-related pathways [4].
Together, these studies illustrate how spatially resolved molecular workflows can link tissue architecture and cellular localization with downstream molecular characterization, which enables more detailed investigation of tumour heterogeneity and microenvironmental complexity.
Figure 2. Two key steps of workflows for spatial cell sorting
MS, mass spectrometry; WGS, whole genome sequencing.
Resolving hidden signals: next-generation biomarkers for oncology
Identification of clinically relevant biomarkers remains challenging because conventional bulk molecular analyses can obscure localized signals within spatially heterogeneous tumour tissues. Spatially resolved cell sorting technologies may address this limitation by enabling enrichment of biomarker signals from rare or spatially localized tumour subpopulations that may be obscured in conventional bulk analyses.
Previous studies using spatially directed isolation approaches have demonstrated the value of localized molecular characterization in heterogeneous tumours. In colorectal cancer, spatial analysis revealed stromal enrichment of nicotinamide N-methyltransferase (NNMT), which was associated with metastasis and unfavourable patient survival [6]. In non-small cell lung cancer (NSCLC), immuno-guided laser-capture microdissection combined with reverse-phase protein profiling enabled molecular characterization of spatially localized neuroendocrine subclones. Distinct kinase signalling activation patterns and potentially druggable molecular targets were identified within these tumour subpopulations [7].
Together, spatially resolved molecular workflows may enable detection of clinically relevant biomarkers that are difficult to resolve using conventional bulk analyses. Selective molecular characterization of spatially defined tumour populations could support future companion diagnostic development, improved prognostic stratification and identification of therapeutically actionable tumour niches in precision oncology settings.
Time and space: monitoring therapeutic response over time
Tumour tissues can undergo dynamic molecular and spatial changes throughout disease progression and different stages of treatment. Over time, resistant tumour subpopulations, altered immune-cell distributions and evolving clonal architectures may emerge or shift, yet these localized changes are not always adequately captured through conventional bulk molecular analysis. Spatially resolved cell sorting technologies provide new opportunities for longitudinal investigation of tumour evolution through selective molecular characterization of spatially defined cellular populations from sequential tissue specimens.
One recent study using the Hema-seq workflow demonstrated how sequential spatial analysis could support treatment-response monitoring in a rare case involving simultaneous plasma cell myeloma and acute myeloid leukemia (AML). By selectively isolating and sequencing spatially defined cellular populations from serial bone marrow specimens collected throughout multiple treatment cycles, investigators were able to monitor dynamic shifts in leukemic blast and plasma cell populations over time.
Integration of cytogenetic profiling, morphology and whole-genome sequencing further enabled characterization of lineage-specific genomic aberrations and clonal evolution associated with differential therapeutic response [8].
In addition, spatial cell sorting technologies compatible with archived formalin-fixed paraffin-embedded (FFPE) tissue specimens may facilitate retrospective longitudinal studies using clinically annotated patient samples collected throughout disease progression and treatment.
Spatially resolved cell sorting approaches may become increasingly integrated into future diagnostic strategies for treatment monitoring, companion diagnostics and precision oncology.
Outlook
As precision oncology continues to evolve, there is growing interest in technologies capable of integrating spatial information with molecular profiling approaches. Spatially resolved cell sorting technologies represent one emerging approach for selectively isolating spatially defined tumour and microenvironmental cellular populations directly from tissue sections while preserving tissue context for downstream molecular analysis.
Future development of spatial cell sorting technologies will likely focus on expanding applicability across a broader range of tumour types while improving integration with multi-omic molecular profiling workflows. Although current applications are most commonly combined with RNA-sequencing-based analysis, integration with DNA sequencing, proteomic and metabolomic technologies may enable more comprehensive characterization of spatially defined cellular populations and localized tumour states. Such advances may further support identification of spatially localized biomarkers, therapeutic targets and resistance-associated molecular programmes within heterogeneous tumour micro-environments.
Broader clinical implementation of spatial molecular workflows will also require continued improvements in scalability, accessibility and workflow standardization. As these technologies continue to mature, imaging-guided spatial cell sorting approaches may contribute to future diagnostic strategies and more individualized therapeutic approaches in precision oncology.
The author
Yoonyoung Lee PhD,
Principal Researcher, Research & Development Team Meteor Biotech, Seoul, South Korea
For further information see: http://meteorbiotech.com
References
1. Wang XQ, Danenberg E, Huang CS et al. Spatial predictors of immunotherapy response in triple-negative breast cancer. Nature. 2023;621(7980):868–876 (https://doi.org/10.1038/s41586-023-06498-3).
2. Ståhl PL, Salmén F, Vickovic S et al. Visualization and analysis of gene expression in tissue sections by spatial transcriptomics. Science. 2016;353(6294):78–82 (https://doi.org/10.1126/science.aaf2403).
3. Emmert-Buck MR, Bonner RF, Smith PD et al. Laser capture microdissection. Science. 1996;274(5289):998–1001 (https://doi.org/10.1126/science.274.5289.998).
4. Lee AC, Lee Y, Choi A et al. Spatial epitranscriptomics reveals A-to-I editome specific to cancer stem cell microniches. Nat Commun. 2022;13:2540 (https://doi.org/10.1038/s41467-022-30299-3).
5. Tay JK, Zhu C, Shin JH et al. The microdissected gene expression landscape of nasopharyngeal cancer reveals vulnerabilities in FGF and noncanonical NF-κB signaling. Sci Adv. 2022;8(14):eabh2445 (https://doi.org/10.1126/sciadv.abh2445).
6. Yang J, Tong Q, Zhang Y et al. Overexpression of nicotinamide N-methyltransferase mainly covers stroma of colorectal cancer and correlates with unfavorable survival by its product 1-MNA. J Cancer. 2021;12(20):6170–6181 (https://doi.org/10.7150/jca.56419).
7. Baldelli E, Mandarano M, Bellezza G et al. Analysis of neuroendocrine clones in NSCLCs using an immuno-guided laser-capture microdissection-based approach. Cell Rep Methods. 2022;2(8):100271 (https://doi.org/10.1016/j.crmeth.2022.100271).
8. Jeong D, Lee AC, Shin K et al. Hema-seq reveals genomic aberrations in a rare simultaneous occurrence of hematological malignancies. Cell Rep Methods. 2023;3(12):100617
(https://doi.org/10.1016/j.crmeth.2023.100617).
